Invivyd
- Company typePublic
- Founded2020
- HeadquartersWaltham, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
Invivyd firmographics
Firmographics- Name
- Invivyd
- Legal name
- Invivyd, Inc.
- Website
- https://invivyd.com
- Company type
- Public
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Ownership category
- akta.pro rank
Invivyd industry classification
Industry- Product category
- Monoclonal Antibody Therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA)
Keywords
Where Invivyd is headquartered
LocationHeadquarters
- HQ city
- Waltham
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Invivyd business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations
Revenue model
- PEMGARDA Product Sales: Net product revenue from sales of PEMGARDA (pemivibart), a monoclonal antibody authorized for emergency use in COVID-19 pre-exposure prophylaxis, marketed primarily to immunocompromised patients who do not respond well to vaccines
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Other | PEMGARDA (pemivibart) for COVID-19 pre-exposure prophylaxis |
Go-to-market motion2 records
Distribution channels1 record
Marketing channels5 records
Invivyd product offering
Product offeringCore offering
Invivyd is a clinical-stage and commercial biopharmaceutical company that discovers, develops, and commercializes monoclonal antibody (mAb) therapies for serious viral infectious diseases. Its commercial product, PEMGARDA (pemivibart), is authorized under FDA Emergency Use Authorization for COVID-19 pre-exposure prophylaxis in immunocompromised adults and adolescents. The company also advances a pipeline of monoclonal antibody candidates (VYD2311 for COVID-19 prevention/treatment and Long COVID, VBY329 for RSV, VMS063 for measles) generated through its proprietary INVYMAB platform that integrates viral surveillance, predictive modeling, deep B-cell mining, and antibody engineering.
Product overview
Invivyd is a biopharmaceutical company with a single commercial product and multiple pipeline candidates. PEMGARDA (pemivibart) is the company's authorized monoclonal antibody for COVID-19 pre-exposure prophylaxis, launched in March 2024. The development pipeline centers on VYD2311 as a next-generation COVID-19 prevention and treatment candidate in Phase 3 trials, with additional indications including Long COVID and a robust expansion pipeline including VBY329 for RSV (prophylaxis in children) and VMS063 for measles, both in development. All candidates leverage the proprietary INVYMAB platform which combines viral surveillance, predictive modeling, antibody discovery through B-cell mining, and antibody engineering for affinity maturation.
Differentiator
Problem solved
Functional benefit
Products and services
- PEMGARDA (pemivibart) A monoclonal antibody authorized for emergency use in COVID-19 pre-exposure prophylaxis for adults and adolescents (12 years of age and older weighing at least 40 kg) with moderate to severe immune compromise who may not respond adequately to COVID-19 vaccination.
- VYD2311 A next-generation monoclonal antibody candidate designed as a vaccine-alternative antibody for COVID-19 prevention, with additional indications under development including Long COVID treatment and COVID-19 treatment; in Phase 3 LIBERTY pivotal trial with Fast Track designation.
- VBY329 (RSV) A selected potential best-in-class monoclonal antibody candidate for respiratory syncytial virus (RSV) prophylaxis targeting children, with increased potency and resistance to RSV variants compared to current treatments; targeting IND readiness in 2H 2026.
- VMS063 (Measles) A novel measles monoclonal antibody candidate targeting the Fusion protein for treatment and prevention of measles; discovered in April 2026 with IND-enabling studies underway and target IND readiness in late 2026.
Quantifiable outcome
- PEMGARDA demonstrated approximately 80% protection against COVID-19 variants in clinical studies versus CDC-estimated 40-50% efficacy for mRNA vaccines in healthy individuals
- +2 more outcomes
Companies that use Invivyd
Customer profileNamed customers4 records
Segments2 records
Ideal customer profiles1 record
Invivyd technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature3 records
Invivyd partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered minor and core.
- Sanofi (COMPARE trial collaboration)minorCollaborative research presentation at ESCMID comparing monoclonal antibody side effect data with Sanofi's COMPARE trial results for protein-based COVID vaccines
- Lindsey VonncoreOlympic gold medalist skier serving as public ambassador for 'Antibodies for Any Body' national education campaign to raise public awareness about antibody-based treatments for disease protection; campaign launched spring 2026 with digital platform and wellness assessment tools
- Jim HarbaughcoreNFL head coach partnered with Invivyd for COVID awareness campaign 'Common, Not A Cold' to educate Americans about ongoing COVID-19 impact and antibody treatment options
Scale indicators8 records
Recent moves6 records
Expansion highlights7 records
Invivyd competitors and assessment
Company assessmentDirect peers
- Vir Biotechnology: Vir Biotechnology develops monoclonal antibodies for serious infectious diseases, including sotrovimab (Xevudy) for COVID-19, and is advancing pipeline candidates for influenza and hepatitis B. It is the most direct peer to Invivyd in terms of mAb-based infectious disease strategy and target indications.
Broad incumbents
- AstraZeneca: AstraZeneca developed Evusheld (tixagevimab/cilgavimab), a long-acting monoclonal antibody combination for COVID-19 pre-exposure prophylaxis, directly competing with PEMGARDA in the immunocompromised patient segment. As a large-cap incumbent, AstraZeneca operates a much broader portfolio and has greater commercial reach.
- Eli Lilly: Eli Lilly developed bebtelovimab, a monoclonal antibody authorized for COVID-19 treatment, and is broadly active in the infectious disease and immunology spaces. As a global pharmaceutical incumbent, Lilly has significantly greater commercial and R&D resources than Invivyd.
- Sanofi: Sanofi is a global biopharmaceutical incumbent with a significant vaccines and immunology franchise, including a COVID-19 protein-based vaccine. Invivyd has a scientific collaboration with Sanofi (COMPARE trial), reflecting Sanofi's role as both a potential partner and a competitor in the infectious disease prevention space.
Others
- Regeneron Pharmaceuticals: Regeneron developed the REGEN-COV (casirivimab/imdevimab) monoclonal antibody cocktail for COVID-19 prevention and treatment. As a large-cap biopharmaceutical incumbent, Regeneron has deep antibody discovery capabilities (VelocImmune) and broad therapeutic focus spanning ophthalmology, oncology, and immunology.
- Adimab: Adimab is a leading antibody discovery technology company that has historically been an investor in Invivyd (Adagio Therapeutics) and operates in the monoclonal antibody discovery and engineering space. It is a potential platform partner or competitor for antibody discovery capabilities underlying mAb-based infectious disease therapeutics.
- Moderna: Moderna is a major competitor in COVID-19 prevention through its mRNA vaccines (Spikevax) and is the direct comparator in Invivyd's Phase 3 LIBERTY trial. While operating in a different modality, Moderna competes for the same prevention market and reimbursement dollars as Invivyd's antibody-based approach.
- Pfizer: Pfizer, in partnership with BioNTech, developed Comirnaty, the leading mRNA COVID-19 vaccine, and is a key competitor in the COVID-19 prevention landscape. Pfizer competes with Invivyd for prescriber attention, payer reimbursement, and patient share in both immunocompromised and general populations.
Emerging players
- Atea Pharmaceuticals: Atea Pharmaceuticals is a clinical-stage biopharmaceutical company developing oral antiviral therapies for RNA viruses, including COVID-19 and hepatitis C. While focused on direct-acting antivirals rather than monoclonal antibodies, Atea targets the same viral disease indications and patient populations as Invivyd.
- Brii Biosciences: Brii Biosciences developed amubarvimab/romlusevimab, a monoclonal antibody combination for COVID-19, primarily serving the China market. It is comparable to Invivyd as an emerging infectious disease mAb developer, though it operates in a distinct geographic and regulatory environment.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
Invivyd social profiles
Digital presenceInvivyd compliance and trust
Trust signalCompliance1 record
Invivyd financial estimates
Financial estimateRevenue estimate
Valuation estimate
Invivyd leadership team
Management profileNumber of profiles
Profiles16 records
Invivyd funding detail
Funding detailFunding overview
Funding rounds6 records
Investors16 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Invivyd M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Invivyd
What does Invivyd do?
Invivyd is a clinical-stage and commercial biopharmaceutical company that discovers, develops, and commercializes monoclonal antibody (mAb) therapies for serious viral infectious diseases. Its commercial product, PEMGARDA (pemivibart), is authorized under FDA Emergency Use Authorization for COVID-19 pre-exposure prophylaxis in immunocompromised adults and adolescents. The company also advances a pipeline of monoclonal antibody candidates (VYD2311 for COVID-19 prevention/treatment and Long COVID, VBY329 for RSV, VMS063 for measles) generated through its proprietary INVYMAB platform that integrates viral surveillance, predictive modeling, deep B-cell mining, and antibody engineering.
Is Invivyd a public or private company?
Invivyd is a public company. It is classified as public and is currently operating.
When was Invivyd founded?
Invivyd was founded in 2020. It employs 101 to 250 people.
Where is Invivyd based?
Invivyd is headquartered in Waltham, United States, in the North America region.
How does Invivyd make money?
One revenue line is on record: PEMGARDA Product Sales.
Who are Invivyd's main competitors?
Vir Biotechnology is listed as a direct peer. Broad incumbents are AstraZeneca, Eli Lilly and Sanofi. Others are Regeneron Pharmaceuticals, Adimab, Moderna and Pfizer. Emerging players are Atea Pharmaceuticals and Brii Biosciences.
Does Invivyd have an API?
No public API is recorded for Invivyd.
What industry is Invivyd in?
Invivyd's product category is Monoclonal Antibody Therapeutics. Its primary akta.pro industry code is HLAAAAAA, Monoclonal Antibody Therapeutics (mAbs). Its NAICS code is 325414 and its SIC code is 2836.